Interview – Jean-Philippe Hecquet, President & CEO of Laboratoires VIVACY
ANTI-AGE MAGAZINE: Mr. Hecquet, you have just taken the helm of VIVACY. What motivated you to join a company in the aesthetic medicine field?
JEAN-PHILIPPE HECQUET: After more than 20 years in the luxury industry, working with outstanding brands such as Louis Vuitton, TAG Heuer, Lanvin and Rémy Martin, I became increasingly interested in the aesthetics industry as I realised that the customers were essentially the same. I observed a strong underlying trend toward self-care, well-being, and the desire to feel better by turning to the very best solutions available on the market. That is when VIVACY stood out to me, as a leading French brand, highly respected by practitioners, with a unique heritage and expertise whose excellence no longer needs to be proven. But I was also drawn to a brand driven by continuous innovation, offering a wide range of highly relevant treatment solutions with extraordinary potential. VIVACY combines high-level scientific rigour, rare creativity in innovation, and a perfectly clear international ambition. Aesthetic medicine is evolving rapidly, and VIVACY already has a head start in its ability to understand the modern patient – one who is no longer seeking simple correction, but a deeper sense of well-being.
AAM: You speak of a transformation within the industry. How does VIVACY fit into this evolution?
JP.H.: We are witnessing a major shift: patients no longer want to “look different,” they want to “feel better.” Aesthetics is becoming an act of well-being, an investment in long-term skin health, confidence, and longevity. VIVACY is fully aligned with this transition. For more than 15 years, we have been developing technologies designed to support the skin’s biological functions rather than merely conceal imperfections. This philosophy centred on natural results, harmony, and long-term sustainability – now guides all of our decisions.
AAM: The concept of “regenerative aesthetics” is central to your new positioning. What does it mean in concrete terms for VIVACY?
JP.H.: For VIVACY, regenerative aesthetics goes far beyond visible improvement. It represents a holistic approach to the skin, aimed at stimulating its natural capabilities to preserve vitality and youthfulness over the long term. Concretely, this means creating solutions that activate the skin’s intrinsic mechanisms, restore essential biological functions, and support its natural evolution over time. This vision is deeply connected to well-being, self-confidence, and longevity. We design our products as true “partners” for the skin – delivering immediate results while, above all, providing measurable and lasting benefits that align with the expectations of today’s patients.
AAM: How is this repositioning reflected in your corporate strategy?
JP.H.: This repositioning permeates our entire organisation. We have rethought our strategy to focus fully on skin regeneration and long-term well-being. This includes increased investment in research, with strengthened clinical studies and scientific collaborations, as well as a product development strategy guided by a clear mission: to improve overall skin quality and support each patient in a journey toward aesthetic longevity.
We have also redefined our relationship with practitioners, offering more precise and safer protocols, increasingly oriented toward natural results and long-lasting outcomes, supported by globally recognised experts. Finally, drawing on my international experience in previous roles, we are accelerating our global expansion, as demand for regenerative and well-being–focused solutions is now strong across many regions worldwide.
AAM: You are known as a “transformational leader.” What kind of leadership do you want to bring to VIVACY?
JP.H.: I have indeed had the opportunity to support remarkable brands through key transformation phases, helping them reach critical milestones. Founded 18 years ago, VIVACY has always been built for the long term, and I am here to write this new chapter alongside talented, highly skilled teams, supported by a strong DNA and a very solid shareholder. Beyond a premium and highly relevant product offering, this transformation will be driven by demanding, inspiring leadership with a clear future-oriented vision. My role is to embody this ambition: to make VIVACY a global leader in regenerative aesthetics. This requires a shared and clearly articulated vision, strong collective momentum, operational excellence, and a culture of innovation in service of both physicians and patients. I have always believed in the power of teams – it is by uniting our talents around a common vision that we will write the next great chapter in VIVACY’s history.
AAM: What will be the first visible milestones of this new strategy in the coming months?
JP.H.: IMCAS Paris 2026 will represent a major milestone for VIVACY and a clear signal to the market. On this occasion, we will unveil two strategic launches that fully embody our new direction. The flagship launch will be REJURAN®, introduced in Europe through a strategic partnership with PharmaResearch for its exclusive distribution across the European market. Already recognised as the number one skin booster in Korea, widely adopted and endorsed by international celebrities, REJURAN® has established itself as a benchmark in skin regeneration. This regenerative solution based on polynucleotides works deep within the skin to improve overall skin quality, strengthen natural biological mechanisms, and support patients in a journey toward well-being and skin longevity. It responds to a strong market demand for visible, progressive, and long-lasting results that respect the integrity of the skin. Alongside it, NOVUMA®, developed in collaboration with Burgeon Biotechnology, complements this approach with a next-generation calcium hydroxyapatite solution dedicated to skin firming. Designed to improve tissue tone and support, NOVUMA® delivers harmonious and stable results while preserving facial naturalness. Together, these two innovations clearly reflect our ambition: to rely on strong scientific partnerships to position VIVACY as an international leader in regenerative aesthetics.
AAM: What message would you like to share today with the international aesthetic medicine industry?
JP.H.: VIVACY is moving forward with a strong conviction: the future of aesthetic medicine will be regenerative, responsible, and centred on well-being. I am firmly convinced that premium brands like VIVACY, built on recognised expertise and impeccable “Made in France” quality, will be the ones still leading the market ten years from now. The market may sometimes appear saturated, but quality, service, and know-how are what truly make the difference. It reminds me of the fashion industry, with mass market, accessible luxury, and true luxury – VIVACY clearly belongs to the latter category. We are building solutions that respect the skin, stimulate it, and strengthen it to meet a profound patient aspiration: to live better, longer, with healthy skin. Our goal is to be a trusted partner for physicians, a visionary player for the industry, and a driving force in advancing the science of skin longevity.
